Latest Pharma and Biotech News
Pharmaceutical
6 January 2025 Patrick Branch, head of Japan and APAC business development at Nxera Pharma,
Japan’s most innovative and nimble biopharma company, provides a summary of the year in the important eastern market.
Today's issue
Refine Search
Pharmaceutical
A team of Chinese researchers has identified a promising candidate for glaucoma treatment using artificial intelligence tools. 6 January 2025
Pharmaceutical
Patrick Branch, head of Japan and APAC business development at Nxera Pharma,
Japan’s most innovative and nimble biopharma company, provides a summary of the year in the important eastern market. 6 January 2025
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca has announced that new, positive, long-term results from the pivotal ALPHA Phase III trial have appeared in the journal Blood, which is published by the American Society of Hematology. 6 January 2025
Pharmaceutical
Alon Natanson, a business leader and alumnus of the Hebrew University of Jerusalem, has been appointed chief executive officer (CEO) of Yissum, the Israeli Hebrew University Tech Transfer company. 6 January 2025
Pharmaceutical
Japanese drugmaker Otsuka Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for the hereditary angioedema(HAE) drug candidate donidalorsen. 6 January 2025
Pharmaceutical
Switzerland’s Santhera Pharmaceuticals has entered an exclusive deal with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in regions where the drug is not yet commercially available. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
All news
Pharmaceutical
The US Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) has released new research showing how key Inflation Reduction Act provisions will lower costs for women enrolled in Medicare, including nearly 30 million women enrolled in Part D. 3 April 2024
Pharmaceutical
A new licensing deal has been agreed between American firm Incyte and Hong Kong-based China Medical System Holdings (CMS). 2 April 2024
Pharmaceutical
Deal flow was heavy in pharmaceutical M&A during March. 2 April 2024
Pharmaceutical
The US regulator has lifted a partial clinical hold affecting research undertaken by New York-based firm ProJenX. 2 April 2024
Pharmaceutical
UK-based specialty CNS-focused pharma company CNX Therapeutics today announce that it has successfully completed the acquisition of two CNS products from the French sales subsidiary of Japan’s Eisai. 2 April 2024
Pharmaceutical
A report released by the non-profit group No Patient Left Behind has claimed that it has found critical flaws in a key metric used by US insurance companies and foreign governments to determine whether to cover prescribed treatments at low out-of-pocket costs. 2 April 2024
Pharmaceutical
The pharma company known as Sosei Group or Sosei Heptares will now go by the name Nxera Pharma. 2 April 2024
Pharmaceutical
Danish pharma trade group Lif has expressed concerns over a new bill that will make it mandatory for companies to set up safety stocks of critical medicines. 2 April 2024
Pharmaceutical
With new legislation on data protection in the offing, The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called on negotiators to take more time to make sure the law is drafted optimally. 2 April 2024
Pharmaceutical
A new collaboration has been agreed between Israel’s Teva Pharmaceutical and Launch Therapeutics, related to the candidate TEV-248, which combines fluticasone and albuterol. 2 April 2024
Pharmaceutical
Swiss contract development and manufacturing organization (CDMO) Lonza today announced that Wolfgang Wienand has been appointed chief executive (CEO). 2 April 2024
Pharmaceutical
Taiho Ventures unit has been selected as a certified venture capital of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED) and has entered into an agreement with AMED. 2 April 2024
Pharmaceutical
Marking a second regulatory authorization, Voydeya (danicopan) has now been approved in the USA as add-on therapy for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). 2 April 2024
Pharmaceutical
Joint Clinical Assessments (JCA) can support getting new innovative cancer medicines to patients faster, if the right balance in evidence generation and assessment to facilitate national decisions on access for these innovations can be found. 2 April 2024
Pharmaceutical
Viatris today announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution). 1 April 2024
Pharmaceutical
US pharma major Bristol Myers Squibb yesterday announced a disappointing update following the initial analysis of results from the first of two induction studies in the Phase III YELLOWSTONE. 29 March 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) as a treatment of classic galactosemia by three months. 29 March 2024
Pharmaceutical
Just as MDMA looked to be leading the charge of psychedelics and related compounds towards market for mental health conditions, a dose of jeopardy has been thrown into the mix. 28 March 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. 28 March 2024
Pharmaceutical
US biopharma Altimmune has claimed that it could have something special on its hands in the highly lucrative obesity field. 28 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze